StockIQpro
NYSE:LCTX

Lineage Cell Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Lineage Cell Therapeutics, Inc.'s revenue grew 53.2% in fiscal 2025 to $14.6M while operating margin fell to −251.6%. Free cash flow was −$19.4M, −133.6% of revenue, and the diluted share count rose 14.9%.Summary generated from Lineage Cell Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$14.6M
Revenue growth+53.2%
Revenue, 5-yr CAGR+51.5%
Gross marginn/a
Operating margin−251.6%
Net margin−436.5%
ROICn/a
Return on equity−103.4%
Debt / equityn/a
Free cash flow−$19.4M
FCF margin−133.6%
Share count change+14.9%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue4159915
Operating income−49−23−25−21−37
Net income−43−26−21−19−64
Free cash flow−241−29−24−19

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)